13.3 Pharmacotherapy Research for Stimulant Use Disorder
Key Takeaways
No medication is FDA-approved for cocaine or methamphetamine use disorder, so every pharmacologic option is off-label and must be presented to the patient as such.
The ADAPT-2 trial produced a 13.6% response rate with extended-release injectable naltrexone plus bupropion versus 2.5% with placebo, an 11.1 percentage point difference and a number needed to treat of about 9.
Mirtazapine reduced methamphetamine use in randomized trials of men who have sex with men, with the added benefit of treating the insomnia that dominates early abstinence.
Topiramate and long-acting amphetamine agonist therapy have the most supportive evidence for cocaine use disorder, particularly in patients who achieve initial abstinence.
Any off-label pharmacotherapy for stimulant use disorder must be layered onto contingency management, which remains the intervention with the largest effect size.
13.3 Pharmacotherapy Research for Stimulant Use Disorder
Quick Answer: No FDA-approved medication exists for cocaine or methamphetamine use disorder. The strongest randomized evidence is ADAPT-2 (extended-release injectable naltrexone 380 mg every 3 weeks plus extended-release bupropion titrated to 450 mg daily): 13.6% response versus 2.5% placebo, an absolute difference of 11.1 percentage points and NNT of about 9. Other agents with supportive randomized data include mirtazapine (methamphetamine), topiramate (cocaine, especially after initial abstinence), and prescription psychostimulant agonist therapy with long-acting mixed amphetamine salts or methylphenidate. All are off-label and all are adjuncts to contingency management.
1. Why the Pharmacology Is Hard
Opioid and alcohol pharmacotherapy works because there is a receptor to occupy or an enzyme to block. Stimulants act on transporters, and the downstream injury is a network problem: depleted dopamine tone, dysregulated glutamate signaling from prefrontal cortex to accumbens, and impaired executive control. There is no single target whose blockade abolishes reinforcement without abolishing normal motivation. This is worth explaining to patients who ask, "Why is there a pill for heroin and not for meth?"
2. Agents With Randomized Evidence
| Agent / regimen | Target | Evidence | Practical notes |
|---|---|---|---|
| XR-naltrexone 380 mg IM q3 weeks + bupropion XL to 450 mg/day | Methamphetamine | ADAPT-2 (NEJM 2021): 13.6% vs 2.5% response; NNT about 9 | Requires 7 to 10 opioid-free days before naltrexone; bupropion lowers seizure threshold; screen for eating disorder and seizure history |
| Mirtazapine 30 mg at bedtime | Methamphetamine (studied in men who have sex with men) | Two randomized trials showed reduced methamphetamine-positive urine samples | Also treats early-abstinence insomnia and appetite loss; sedation and weight gain are the limiting effects |
| Topiramate titrated to 200–300 mg/day | Cocaine | Randomized data favor benefit, strongest in patients who achieve initial abstinence | Cognitive dulling, paresthesias, metabolic acidosis, nephrolithiasis, weight loss; teratogenic |
| Long-acting prescription psychostimulants (mixed amphetamine salts ER, methylphenidate ER) | Cocaine and methamphetamine, especially with comorbid ADHD | Agonist-substitution trials show reduced use at higher doses | Diversion and cardiovascular risk require structured monitoring, PDMP review and limited supply |
| Bupropion alone | Methamphetamine | Benefit limited to lower-frequency users in earlier trials; ADAPT-2 tested it only in combination | Not a stand-alone answer for daily heavy use |
| Naltrexone alone | Amphetamine (Swedish trials) | Modest reduction in amphetamine use | Weaker evidence than the combination |
| Modafinil | Cocaine | Mixed; possible benefit in patients without comorbid alcohol use disorder | Not first line |
| Disulfiram | Cocaine | Older trials suggested benefit via dopamine beta-hydroxylase inhibition; later trials inconsistent | Not recommended as routine care |
Agents to know as negatives: antipsychotics do not treat stimulant use disorder and worsen dysphoria and adherence; SSRIs have repeatedly failed; and there is no evidence supporting "detox protocols" with scheduled benzodiazepines for stimulant withdrawal.
3. Interpreting ADAPT-2 for Patients and Colleagues
ADAPT-2 randomized 403 adults with moderate-to-severe methamphetamine use disorder across NIDA Clinical Trials Network sites in a two-stage, double-blind, placebo-controlled design. Response required at least 3 of 4 methamphetamine-negative urine samples during the final two weeks of each stage.
- Response: 13.6% active versus 2.5% placebo; difference 11.1 percentage points (Wald z = 4.53).
- NNT = 1 divided by 0.111, which is about 9.
Two honest framings the APRN should be able to deliver:
- To a colleague who dismisses it: "An NNT of 9 for a condition with no approved therapy is meaningful. We accept comparable numbers in cardiology."
- To a patient: "Most people in that study did not reach the strict abstinence endpoint. What the medication reliably does for some people is take the edge off craving so the rest of the plan has room to work. It is not the plan by itself."
4. Prescribing Safely Off-Label
- Document the off-label discussion. Record that the patient was told the agent is not FDA-approved for this indication, the magnitude of expected benefit, the alternatives including contingency management, and the specific risks.
- Screen before naltrexone. Confirm 7 to 10 opioid-free days (14 for methadone) and check liver function. In the fentanyl era, confirm the opioid-free interval carefully — patients frequently underestimate residual depot fentanyl.
- Screen before bupropion. Absolute contraindications are seizure disorder, current or prior bulimia or anorexia nervosa, abrupt discontinuation of alcohol or sedatives, and MAOI use within 14 days.
- Screen before topiramate. Pregnancy status and contraception plan, renal stones, and baseline cognitive function.
- Set a stop rule. Define in advance what constitutes non-response (for example, no reduction in use frequency and no reduction in craving at 12 weeks) and discontinue rather than accumulating ineffective medications. The 2025 practice analysis added a specific activity statement for this: "Evaluates the need for continuation or discontinuation of pharmacologic agents."
A patient with severe methamphetamine use disorder asks why the APRN is recommending an off-label medication combination rather than "the approved one." Which response is accurate?
Bupropion is FDA-approved for methamphetamine use disorder but is often used at off-label doses.
There are no FDA-approved medications for methamphetamine or cocaine use disorder, so all pharmacotherapy is off-label; the strongest randomized evidence supports extended-release naltrexone plus bupropion, which produced a number needed to treat of about 9 in the ADAPT-2 trial.
Extended-release naltrexone received FDA approval for methamphetamine use disorder after the ADAPT-2 trial.
Modafinil is the approved first-line agent, and the combination regimen is reserved for treatment failure.
An APRN is considering mirtazapine for a patient with methamphetamine use disorder who also reports severe insomnia and weight loss in early abstinence. Which statement best supports this choice?
Mirtazapine blocks the dopamine transporter and prevents methamphetamine from producing euphoria.
Mirtazapine is FDA-approved for stimulant use disorder when insomnia is present.
Mirtazapine is contraindicated in stimulant use disorder because of serotonin syndrome risk with residual methamphetamine.
Randomized trials have shown mirtazapine reduces methamphetamine-positive urine samples, and its sedating and appetite-stimulating effects also address the insomnia and weight loss of early abstinence.
A patient with cocaine use disorder has been taking topiramate 200 mg daily for 14 weeks. She reports no reduction in cocaine use frequency and no reduction in craving, and she describes worsening word-finding difficulty. What does the 2025 CARN-AP blueprint activity "evaluates the need for continuation or discontinuation of pharmacologic agents" indicate the APRN should do?
Continue topiramate indefinitely, since discontinuation risks rebound craving.
Add a second off-label agent while continuing topiramate, since combination therapy is always superior.
Increase the topiramate dose to 400 mg daily, since cognitive effects indicate the dose is therapeutic.
Discontinue topiramate against a predefined non-response rule, address the adverse cognitive effect, and redirect resources to contingency management and other evidence-based options.
Sections you finish are checked off in the contents.